The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
Open accessAbstract
BACKGROUND AND AIMS: Treatment with infliximab induces remission in about 70% of patients with steroid refractory Crohn's disease. Because Crohn's disease is considered to be mediated by uncontrolled activation of mucosal T lymphocytes, we hypothesised that infliximab could induce apoptosis of T lymphocytes. METHODS: Induction of apoptosis in vivo was studied in 10 patients with therapy refractory Crohn's disease. In vitro, resting or stimulated Jurkat T cells were incubated with infliximab. RESULTS: Infusion of infliximab (5 mg/kg) in steroid refractory patients with Crohn's disease induced a clinical response in 9/10 patients but did not influence expression of activation markers, homing receptors, memory cells, Fas expression, or Bax/Bcl-2 expression on peripheral blood T lymphocytes. In contrast, a significant increase in CD3 and TUNEL positive cells within colonic biopsies was detected 24 hours after infusion of infliximab, suggesting that infliximab stimulates apoptosis of activated T lymphocytes but not of resting T cells. To test this hypothesis, the effects of infliximab on Jurkat T cells were investigated. We observed that infliximab induced apoptosis and an increase in the Bax/Bcl-2 ratio of CD3/CD28 stimulated Jurkat T cells but not of unstimulated Jurkat cells. CONCLUSIONS: Our data indicate that infliximab treatment causes a rapid and specific increase in apoptosis of T lymphocytes in the gut mucosa. These findings may explain the rapid and sustained therapeutic effects of infliximab in Crohn's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death
Oltval, Z. N., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)90509-o · Cited by 6,003
The Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
The proto-oncogene Bcl-2 and its role in regulating apoptosis
Kroemer, G. (1997) · Nature Medicine · doi:10.1038/nm0697-614 · Cited by 1,739
Experimental models of inflammatory bowel disease
Elson, C. O., Sartor, R. B., Tennyson, G. S., & Riddell, R. H. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90599-5 · Cited by 1,212
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
van Dullemen, H. M., van Deventer, S. J. H., Hommes, D. W., Bijl, H. A., Jansen, J., Tytgat, G. N. J., & Woody, J. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90277-5 · Cited by 1,084
Homeostasis and Self-Tolerance in the Immune System: Turning Lymphocytes off
Parijs, L. V., & Abbas, A. K. (1998) · Science · doi:10.1126/science.280.5361.243 · Cited by 965
D'Haens, G., Van Deventer, S., Van Hogezand, R., Chalmers, D., Kothe, C., Baert, F., Braakman, T., Schaible, T., Geboes, K., & Rutgeerts, P. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70005-3 · Cited by 745
Molecular Basis of T Cell Inactivation by CTLA-4
Lee, K.-M., Chuang, E., Griffin, M., Khattri, R., Hong, D. K., Zhang, W., Straus, D., Samelson, L. E., Thompson, C. B., & Bluestone, J. A. (1998) · Science · doi:10.1126/science.282.5397.2263 · Cited by 684
Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
Braegger, C. P., Nicholls, S., Murch, S. H., MacDonald, T. T., & Stephens, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)90999-j · Cited by 683
Scallon, B. (1995) · Cytokine · doi:10.1006/cyto.1995.0029 · Cited by 675
Breese, E. J., Michie, C. A., Nicholls, S. W., Murch, S. H., Williams, C. B., Domizio, P., Walker-Smith, J. A., & Macdonald, T. T. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90398-0 · Cited by 566
Aarden, L. A., Groot, E. R. D., & Feltkamp, T. E. W. (1975) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1975.tb29197.x · Cited by 563
Infliximab for the treatment of fistulas in patients with Crohn's disease
Ricart, E., & Sandborn, W. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70414-2 · Cited by 519
Tumour necrosis factor and Crohn's disease.
Van Deventer, S. J. (1997) · Gut · doi:10.1136/gut.40.4.443 · Cited by 500
Baert, F. J., D'Haens, G. R., Peeters, M., Hiele, M. I., Schaible, T. F., Shealy, D., Geboes, K., & Rutgeerts, P. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70224-6 · Cited by 462
Genestier, L., Paillot, R., Fournel, S., Ferraro, C., Miossec, P., & Revillard, J. P. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2676 · Cited by 459
Cytokine-induced survival of activated T cells in vitro and in vivo
Vella, A. T., Dow, S., Potter, T. A., Kappler, J., & Marrack, P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3810 · Cited by 393
CURRENT CONCEPTS OF THE ETIOLOGY AND PATHOGENESIS OF ULCERATIVE COLITIS AND CROHN’S DISEASE
Sartor, R. B. (1995) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(21)00207-7 · Cited by 384
Akbar, A. N., Borthwick, N. J., Wickremasinghe, R. G., Panayiotidis, P., Pilling, D., Bofill, M., Krajewski, S., Reed, J. C., & Salmon, M. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260204 · Cited by 348
Ina, K., Itoh, J., Fukushima, K., Kusugami, K., Yamaguchi, T., Kyokane, K., Imada, A., Binion, D. G., Musso, A., West, G. A., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.2.1081 · Cited by 345
A major role for matrix metalloproteinases in T cell injury in the gut
Pender, S. L., Tickle, S. P., Docherty, A. J., Howie, D., Wathen, N. C., & MacDonald, T. T. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.4.1582 · Cited by 326
Boirivant, M., Marini, M., Di Felice, G., Pronio, A. M., Montesani, C., Tersigni, R., & Strober, W. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70177-0 · Cited by 268
Paleolog, E. M., Hunt, M., Elliott, M. J., Feldmann, M., Maini, R. N., & Woody, J. N. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390703 · Cited by 240
Genestier, L., Fournel, S., Flacher, M., Assossou, O., Revillard, J.-P., & Bonnefoy-Berard, N. (1998) · Blood · doi:10.1182/blood.v91.7.2360 · Cited by 217
Brady, H. J. M., Salomons, G. S., Bobeldijk, R. C., & Berns, A. J. M. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00463.x · Cited by 126
Fas-independent death of activated CD4 + T lymphocytes induced by CTLA-4 crosslinking
Scheipers, P., & Reiser, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.10083 · Cited by 121
Pender, M. P. (1998) · The Lancet · doi:10.1016/s0140-6736(05)60642-3 · Cited by 110
CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study.
Stronkhorst, A., Radema, S. A., Yong, S. L., Bijl, H. M., ten Berge, I. J. M., Tytgat, G. N. J., & van Deventer, S. J. H. (1997) · Gut · doi:10.1136/gut.40.3.320 · Cited by 107
NF-κB regulates Fas / APO-1 / CD95- and TCR-mediated apoptosis of T lymphocytes
Dudley, E. C., Hornung, F., Zheng, L., Scherer, D. C., Ballard, D. W., & Lenardo, M. J. (1999) · European Journal of Immunology · Cited by 87
Caspase-dependent Ceramide Production in Fas- and HLA Class I-mediated Peripheral T Cell Apoptosis
Genestier, L., Prigent, A., Paillot, R., Quemeneur, L., Durand, I., Banchereau, J., Revillard, J., & Bonnefoy, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.5060 · Cited by 67
The Action of Bax and Bcl-2 on T Cell Selection
Williams, O., Norton, T., Halligey, M., Kioussis, D., & Brady, H. J. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.6.1125 · Cited by 57
Measurements of Antibodies Specific for DNA
Aarden, L. A., & Smeenk, R. J. T. (1981) · Elsevier eBooks · doi:10.1016/b978-0-12-442702-0.50010-8 · Cited by 42
Tumour necrosis factor and inflammatory bowel disease
Armstrong, A. M., Gardiner, K. R., Kirk, S., HALLIDAY, M. I., & Rowlands, B. J. (1997) · British journal of surgery · doi:10.1002/bjs.1800840805 · Cited by 35
Ricketts, R. R. (2000) · Journal of Pediatric Surgery · doi:10.1016/s0022-3468(00)90238-0 · Cited by 23
Cited by
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Podolsky, D. K. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020831 · Cited by 3,159
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis
Sartor, R. B. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0528 · Cited by 1,757
Metadata
- Authors
- ten Hove, T.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2002-02-01
- Volume
- 50
- Issue
- 2
- Pages
- 206-211
- ISSN
- 0017-5749 (ISSN-L)
- OpenAlex
- W1922746363
- Cited by
- 545
- References
- 37
- FWCI
- 28.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.